- Home
- ONCO vs PBM Comparison
ONCO vs PBM Comparison
Compare ONCO & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- PBM
- Stock Information
- Founded
- ONCO 2018
- PBM 1994
- Country
- ONCO United States
- PBM Canada
- Employees
- ONCO N/A
- PBM N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- PBM
- Sector
- ONCO Health Care
- PBM
- Exchange
- ONCO Nasdaq
- PBM NYSE
- Market Cap
- ONCO 5.8M
- PBM 5.3M
- IPO Year
- ONCO 2022
- PBM N/A
- Fundamental
- Price
- ONCO $0.40
- PBM $1.30
- Analyst Decision
- ONCO
- PBM
- Analyst Count
- ONCO 0
- PBM 0
- Target Price
- ONCO N/A
- PBM N/A
- AVG Volume (30 Days)
- ONCO 9.9M
- PBM 367.3K
- Earning Date
- ONCO 04-10-2025
- PBM 02-02-2025
- Dividend Yield
- ONCO N/A
- PBM N/A
- EPS Growth
- ONCO N/A
- PBM N/A
- EPS
- ONCO N/A
- PBM N/A
- Revenue
- ONCO $1,870,605.00
- PBM N/A
- Revenue This Year
- ONCO N/A
- PBM N/A
- Revenue Next Year
- ONCO N/A
- PBM N/A
- P/E Ratio
- ONCO N/A
- PBM N/A
- Revenue Growth
- ONCO N/A
- PBM N/A
- 52 Week Low
- ONCO $0.32
- PBM $1.15
- 52 Week High
- ONCO $21.40
- PBM $323.25
- Technical
- Relative Strength Index (RSI)
- ONCO 33.18
- PBM 38.56
- Support Level
- ONCO $0.58
- PBM $1.15
- Resistance Level
- ONCO $0.70
- PBM $1.47
- Average True Range (ATR)
- ONCO 0.06
- PBM 0.13
- MACD
- ONCO -0.01
- PBM 0.04
- Stochastic Oscillator
- ONCO 0.00
- PBM 34.09
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.